Bausch Health Companies Inc. (NYSE:BHC – Get Rating) saw a significant drop in short interest in the month of December. As of December 30th, there was short interest totalling 26,620,000 shares, a drop of 14.1% from the December 15th total of 30,980,000 shares. Based on an average daily trading volume, of 5,100,000 shares, the days-to-cover ratio is presently 5.2 days. Approximately 7.5% of the company's stock are short sold.

Institutional Investors Weigh In On Bausch Health Companies

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Paulson & CO. Inc. lifted its stake in shares of Bausch Health Companies by 2.3% during the second quarter. Paulson & CO. Inc. now owns 26,439,035 shares of the company's stock worth $221,030,000 after buying an additional 600,000 shares during the period. Vanguard Group Inc. lifted its stake in shares of Bausch Health Companies by 2.0% during the third quarter. Vanguard Group Inc. now owns 10,924,375 shares of the company's stock worth $75,268,000 after buying an additional 219,279 shares during the period. Segantii Capital Management Ltd lifted its stake in shares of Bausch Health Companies by 281.3% during the second quarter. Segantii Capital Management Ltd now owns 5,700,000 shares of the company's stock worth $47,652,000 after buying an additional 4,205,000 shares during the period. Fiera Capital Corp lifted its stake in shares of Bausch Health Companies by 12.9% during the second quarter. Fiera Capital Corp now owns 3,445,746 shares of the company's stock worth $28,807,000 after buying an additional 393,903 shares during the period. Finally, Rubric Capital Management LP acquired a new stake in shares of Bausch Health Companies during the third quarter worth $22,492,000. 66.99% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Bausch Health Companies in a report on Wednesday, October 12th. They set a "hold" rating on the stock. Five analysts have rated the stock with a hold rating, According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $10.60.

Bausch Health Companies Stock Up 2.7 %

Bausch Health Companies (NYSE:BHC – Get Rating) last released its quarterly earnings results on Thursday, November 3rd. The company reported $0.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.16). Bausch Health Companies had a return on equity of 942.47% and a net margin of 3.13%. The firm had revenue of $2.05 billion during the quarter, compared to analysts' expectations of $2.09 billion. Equities research analysts anticipate that Bausch Health Companies will post 2.97 earnings per share for the current year.

Bausch Health Companies Company Profile

(Get Rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

Read More

• Get a free copy of the StockNews.com research report on Bausch Health Companies (BHC)
• Tractor Supply Company Shares Could be Headed to New Highs
• Is Canadian Solar Too Hot to Handle?
• UiPath is the Blue-Collar AI Platform to Watch in 2023
• CVS Health is Growing into an Integrated Healthcare Organization
• Is C3.ai Stock a ChatGPT Artificial Intelligence Play?

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.